HiRO acquires CRO DeltaMed Solutions, continues to expand cross-border operations in the US, Business News

HiRO’s Strategic Growth Through Acquisitions

Harvest Integrated Research Organization (HiRO) has rapidly positioned itself as a leading global CRO by pursuing a strategy centered on targeted acquisitions. Since its establishment in 2020, HiRO has acquired ANZ-based PharmaSols in 2021 and US-based Courante Oncology in 2022. Each acquisition has expanded its capabilities and geographic footprint, helping it evolve into a comprehensive clinical research provider.

The acquisition of DeltaMed Solutions marks a continuation of this growth trajectory. By integrating a company with a strong foothold in the US market, HiRO strengthens its cross-border operational capabilities and client base. This approach allows HiRO to offer more flexible, capital-efficient clinical trial solutions tailored to the specific needs of pharmaceutical and biotech companies worldwide.

Advised by Evercore as its financial advisor, HiRO’s acquisition strategy reflects a deliberate and well-planned effort to build a global network of CRO services. This network is designed to address the increasingly complex demands of international drug development, regulatory submissions, and clinical trial management.

DeltaMed Solutions: A Robust US-Based CRO

DeltaMed Solutions is a well-established CRO headquartered in New Jersey, known for its strong presence in the US market. The company boasts a seasoned leadership team with 15 to 30 years of experience serving mid- to large-sized pharmaceutical and biotechnology clients. This expertise covers a broad spectrum of clinical research functions essential to drug development.

The company specializes in data management, biostatistics, programming, real-world evidence (RWE) solutions, pharmacokinetics/pharmacodynamics (PK/PD) analysis, regulatory affairs, and medical affairs. These services have earned DeltaMed a reputation for quality, flexibility, and client-centric service delivery, making it a valuable addition to HiRO’s portfolio.

DeltaMed’s leadership brings deep knowledge of FDA and EMEA regulatory submissions, which is critical for navigating the increasingly stringent and complex regulatory environments in the US and Europe. Their expertise enhances HiRO’s ability to deliver seamless regulatory strategies for global clinical trials.

Enhancing Global Clinical Research Capabilities

The integration of DeltaMed Solutions into HiRO’s operations significantly broadens the combined entity’s therapeutic expertise and service offerings. This synergy enables HiRO to provide a more comprehensive suite of clinical trial services, including advanced data analytics, regulatory consulting, and real-world evidence generation.

HiRO’s existing footprint spans Mainland China, Taiwan, Japan, South Korea, Malaysia, the Philippines, Australia, New Zealand, and Ireland, positioning it as a truly global CRO. Adding DeltaMed’s US presence creates a seamless cross-border platform that can efficiently manage clinical trials across multiple continents.

This expanded global capability is particularly valuable in today’s pharmaceutical landscape, where drug development increasingly requires multinational collaboration and coordination. HiRO’s enhanced network allows clients to accelerate trial timelines, reduce costs, and ensure compliance with diverse regulatory requirements.

Leadership Perspectives on the Acquisition

Dr. Karen Chu, Founder and CEO of HiRO, expressed strong confidence in the acquisition, emphasizing its alignment with HiRO’s growth strategy. She highlighted the combined resources and expertise as key to delivering superior clinical trial services that exceed industry standards and foster innovation in patient treatments.

Dr. Chu also pointed out that the collaboration leverages strengths across therapeutic areas and geographic regions, positioning HiRO as a pioneering force in the competitive CRO industry. She underscored the importance of efficiency and effectiveness in advancing clinical trials globally.

From DeltaMed Solutions’ side, President Dr. Sam Liang welcomed the integration, noting the opportunity to contribute scientific expertise and a well-established US presence. He emphasized the shared commitment to quality, innovation, and patient-centric research, which will drive accelerated development of groundbreaking therapies.

Implications for the Pharmaceutical and Biotech Industry

HiRO’s acquisition of DeltaMed Solutions is poised to impact the pharmaceutical and biotech sectors by enhancing access to comprehensive and customized clinical research services. This integration supports faster, more efficient clinical trials, which are crucial for bringing new treatments to market in a timely manner.

The combined CRO’s ability to navigate complex regulatory landscapes and deliver end-to-end solutions reduces barriers for companies conducting multi-regional studies. This is particularly important for biotech firms and smaller pharmaceutical companies that require flexible and capital-efficient partnerships.

By expanding its service offerings and geographic reach, HiRO strengthens its position as a preferred partner for clinical development, enabling clients to optimize resources and accelerate innovation in a competitive marketplace.

Cross-Border Operations and Market Expansion

The acquisition significantly enhances HiRO’s cross-border operational capabilities, facilitating smoother coordination of clinical trials between the US and Asia-Pacific regions. This integration allows for the harmonization of protocols, data collection, and regulatory submissions across diverse markets.

HiRO’s expanded network supports clients in navigating market-specific complexities, including differing regulatory requirements, cultural nuances, and patient recruitment challenges. These capabilities are critical in delivering effective clinical trial solutions globally.

Furthermore, the acquisition positions HiRO to capitalize on the growing demand for integrated clinical research services that span multiple geographies, reinforcing its competitive advantage in an increasingly globalized pharmaceutical industry.

Future Outlook and Industry Positioning

Looking ahead, HiRO’s acquisition of DeltaMed Solutions is expected to accelerate its growth and innovation trajectory. The company is well-positioned to leverage combined expertise in data management, regulatory affairs, and therapeutic areas to meet evolving client needs.

HiRO’s commitment to delivering capital-efficient and expedited clinical trial solutions aligns with industry trends emphasizing patient-centric research, real-world evidence, and adaptive trial designs. This positions the company to remain at the forefront of clinical research innovation.

As the global CRO market becomes more competitive, HiRO’s expanded capabilities and cross-border presence will enable it to differentiate itself by offering tailored solutions that address complex drug development challenges across multiple regions.

Conclusion

The acquisition of DeltaMed Solutions by Harvest Integrated Research Organization marks a pivotal step in HiRO’s expansion strategy, reinforcing its position as a global leader in clinical research services. By combining resources, expertise, and geographic reach, HiRO is better equipped to deliver comprehensive, efficient, and innovative clinical trial solutions tailored to the evolving needs of pharmaceutical and biotechnology clients. This cross-border integration not only accelerates drug development timelines but also enhances regulatory navigation and patient-centric research initiatives. As HiRO continues to grow through strategic acquisitions and organic development, it sets a new standard for excellence and collaboration in the competitive CRO industry, ultimately contributing to improved healthcare outcomes worldwide.